Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580032 · ClinicalTrials.gov registry record
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
A clinical trial of Growth Disorder and Growth Hormone Deficiency in Children, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 252
- Enrollment target
- 20
- Study locations
NCT02580032: Completed study of Growth Disorder and Growth Hormone Deficiency in Children, sponsored by Novo Nordisk A/S.
NCT02580032 is a study of Growth Disorder and Growth Hormone Deficiency in Children that has completed, run by Novo Nordisk A/S. The registered enrollment target is 252 participants. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02580032, a study of Growth Disorder and Growth Hormone Deficiency in Children, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD).
Conditions Studied
Interventions
- OTHER No treatment given
Study Locations (20)
New York
- Novo Nordisk Investigational Site - Albany
- Novo Nordisk Investigational Site - Buffalo
- Novo Nordisk Investigational Site - Mineola
- Novo Nordisk Investigational Site - New York
- Novo Nordisk Investigational Site - Spring Valley
Florida
- Novo Nordisk Investigational Site - Margate
- Novo Nordisk Investigational Site - Miami
- Novo Nordisk Investigational Site - Tallahassee
Arizona
- Novo Nordisk Investigational Site - Phoenix
Colorado
- Novo Nordisk Investigational Site - Centennial
Delaware
- Novo Nordisk Investigational Site - Wilmington
Georgia
- Novo Nordisk Investigational Site - Atlanta
Illinois
- Novo Nordisk Investigational Site - Wheaton
Iowa
- Novo Nordisk Investigational Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2015-10-05 |
| Est. Completion | 2018-05-14 |
What the finished NCT02580032 record still lists
NCT02580032 is an observational study that tracks outcomes without assigning an intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Growth Disorder appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.
NCT02580032 names 20 study sites across 14 states, led by New York, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02580032 about?
NCT02580032 is a clinical study titled "Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)". This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood ...
What is the current status of trial NCT02580032?
This trial is currently completed. The enrollment target is 252 participants. The study started on 2015-10-05. Estimated completion is 2018-05-14.
What conditions does trial NCT02580032 study?
This clinical trial studies the following conditions: Growth Disorder, Growth Hormone Deficiency in Children.
What interventions are being tested in trial NCT02580032?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT02580032?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02580032 being conducted?
This trial has 20 study locations across Arizona, Colorado, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI